Hurlstone D P, Sanders D S, Cross S S, George R, Shorthouse A J, Brown S
Gastroenterology and Liver Unit at the Royal Hallamshire Hospital Sheffield, Sheffield, UK.
Colorectal Dis. 2005 Jul;7(4):339-44. doi: 10.1111/j.1463-1318.2005.00813.x.
Endoscopic mucosal resection is a safe resection tool for selected flat, sessile and lateral spreading tumours of the colon. Transanal microsurgical resection of select rectal neoplastic lesions is another accepted modality. Recent data suggests transanal microsurgery may have high complication rates. We conducted a prospective clinicopathological evaluation of an extended endoscopic mucosal resection technique for highly selected lesions of the rectum and assessed outcome data over a maximal 24-month period.
Eighty-three patients with known rectal neoplastic lesions underwent chromoscopic colonoscopy and on-table staging using a high-frequency (12.5 MHz) mini-probe EUS by a single endoscopist. Patients with T2 or node positive disease were referred for surgery. Following extended endoscopic mucosal resection patients were followed-up at 3, 6, 12 and 24 months post 'index' resection with chromoscopic endoscopy and EUS. Procedural complications, recurrence rates and outcome data were collected.
Sixty-two patients fulfilled inclusion criteria. Median procedure time was 48 mins (range 32-126). Lateral spreading tumours (median diameter 30 mm; range 18-42 mm) and sessile lesions (median diameter 38 mm; range 25-86 mm) accounted for 19% and 81% of lesions, respectively. Ninety-seven percent of patients undergoing EMR were discharged within 6-h of procedure. Thirty-day re-admission and death rate was 0%. Bleeding complications occurred in 5/62 (8%) of patients with all achieving complete haemostasis using endo clips. None required transfusion. There were no procedural related complications or perforations. Overall 'cure' rate at a median follow-up of 16 months was 98%.
Extended endoscopic mucosal resection for rectal neoplastic lesions can achieve superior results to those of per-anal excision and trans-anal microsurgery with regard to complications and recurrence rates. Extended endoscopic mucosal resection may be an alternative therapeutic modality in selected patients.
内镜黏膜切除术是一种用于治疗特定类型结肠扁平、无蒂及侧向扩散肿瘤的安全切除工具。经肛门显微手术切除特定的直肠肿瘤性病变是另一种被认可的治疗方式。近期数据表明经肛门显微手术可能具有较高的并发症发生率。我们对一种用于高度选择的直肠病变的扩展内镜黏膜切除技术进行了前瞻性临床病理评估,并在最长24个月的时间内评估了结果数据。
83例已知直肠肿瘤性病变的患者接受了染色结肠镜检查,并由一名内镜医师使用高频(12.5兆赫)微型探头超声内镜进行术中分期。T2期或淋巴结阳性疾病患者被转诊接受手术。在进行扩展内镜黏膜切除术后,患者在“索引”切除术后3、6、12和24个月接受染色内镜检查和超声内镜随访。收集手术并发症、复发率及结果数据。
62例患者符合纳入标准。手术中位时间为48分钟(范围32 - 126分钟)。侧向扩散肿瘤(中位直径30毫米;范围18 - 42毫米)和无蒂病变(中位直径38毫米;范围25 - 86毫米)分别占病变的19%和81%。97%接受内镜黏膜切除术的患者在术后6小时内出院。30天再入院率和死亡率为0%。5/62(8%)的患者出现出血并发症,所有患者均使用内镜夹实现了完全止血。无人需要输血。无手术相关并发症或穿孔。中位随访16个月时的总体“治愈”率为98%。
对于直肠肿瘤性病变,扩展内镜黏膜切除术在并发症和复发率方面可取得优于经肛门切除和经肛门显微手术的结果。扩展内镜黏膜切除术可能是特定患者的一种替代治疗方式。